Table 3.

Survival and response of mRCC to IL-2 (PROCLAIM) by Heng criteria

	Favorable (median survival, months)	Intermediate (median survival, months)	Poor (median survival, months)
PROCLAIMa	63.7 (n = 37)	34.3 (n = 95)	18.4 (n = 17)
Hengb	Not reached	27	8.8
Motzerc	20	10	4

PROCLAIM response by Heng model	Favorable		Intermediate		Poor
	N	%	N	%	N	%
CR	2	5.4	9	9.5	0	0
PR	1	2.7	4	4.2	3	17.7
SD	9	24.3	17	17.9	5	29.4
PD	25	67.6	60	63.2	7	41.2
Missing	0	0	5	5.3	2	11.8
Total	37	100	95	100	17	100

Responses were based on patients with available data

^aPROCLAIM median follow-up was 46.6 months

^bHeng DY et al., JCO 2009, 27(34): 5794–9. Median follow-up was 24.5 months

^cMotzer RJ et al., JCO 1999, 17(8): 2530–40. Median follow-up was 33 months